BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24944315)

  • 1. Prostate cancer SubtyPINg biomarKers and outcome: is clarity emERGing?
    Smith SC; Tomlins SA
    Clin Cancer Res; 2014 Sep; 20(18):4733-6. PubMed ID: 24944315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
    Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
    Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.
    Fontugne J; Davis K; Palanisamy N; Udager A; Mehra R; McDaniel AS; Siddiqui J; Rubin MA; Mosquera JM; Tomlins SA
    Mod Pathol; 2016 Feb; 29(2):157-65. PubMed ID: 26743468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
    Bhalla R; Kunju LP; Tomlins SA; Christopherson K; Cortez C; Carskadon S; Siddiqui J; Park K; Mosquera JM; Pestano GA; Rubin MA; Chinnaiyan AM; Palanisamy N
    Mod Pathol; 2013 Jun; 26(6):835-48. PubMed ID: 23348902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.
    Brooks JD; Wei W; Hawley S; Auman H; Newcomb L; Boyer H; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; McKenney JK
    PLoS One; 2015; 10(7):e0132343. PubMed ID: 26172920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
    Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
    Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.
    Smith SC; Palanisamy N; Zuhlke KA; Johnson AM; Siddiqui J; Chinnaiyan AM; Kunju LP; Cooney KA; Tomlins SA
    Am J Surg Pathol; 2014 May; 38(5):615-26. PubMed ID: 24722062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPINK1 protein expression and prostate cancer progression.
    Flavin R; Pettersson A; Hendrickson WK; Fiorentino M; Finn S; Kunz L; Judson GL; Lis R; Bailey D; Fiore C; Nuttall E; Martin NE; Stack E; Penney KL; Rider JR; Sinnott J; Sweeney C; Sesso HD; Fall K; Giovannucci E; Kantoff P; Stampfer M; Loda M; Mucci LA
    Clin Cancer Res; 2014 Sep; 20(18):4904-11. PubMed ID: 24687926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
    Grupp K; Diebel F; Sirma H; Simon R; Breitmeyer K; Steurer S; Hube-Magg C; Prien K; Pham T; Weigand P; Michl U; Heinzer H; Kluth M; Minner S; Tsourlakis MC; Izbicki JR; Sauter G; Schlomm T; Wilczak W
    Prostate; 2013 Nov; 73(15):1690-8. PubMed ID: 23843146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.
    Lippolis G; Edsjö A; Stenman UH; Bjartell A
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):145-50. PubMed ID: 23459095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic significance of mutually exclusive expression of ERG and SPINK1 in endocrine-treated prostatic cancer].
    Teng L; Gao W; Lu D; Xu J; Zhao L
    Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):149-53. PubMed ID: 24842011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men.
    Koide H; Kimura T; Inaba H; Sato S; Iwatani K; Yorozu T; Furusato B; Kamata Y; Miki J; Kiyota H; Takahashi H; Egawa S
    Prostate; 2019 Jan; 79(1):3-8. PubMed ID: 30051483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance and EZH2, ERG and SPINK1 protein expression in pure and mixed ductal adenocarcinoma of the prostate.
    Patil PA; McKenney JK; Reynolds JP; Przybycin CG; Magi-Galluzzi C
    Histol Histopathol; 2019 Apr; 34(4):381-390. PubMed ID: 30246858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
    Huang KC; Evans A; Donnelly B; Bismar TA
    Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
    Bismar TA; Yoshimoto M; Duan Q; Liu S; Sircar K; Squire JA
    Histopathology; 2012 Mar; 60(4):645-52. PubMed ID: 22260502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
    Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
    Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
    Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
    Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of SPINK1 in ETS rearrangement-negative prostate cancers.
    Tomlins SA; Rhodes DR; Yu J; Varambally S; Mehra R; Perner S; Demichelis F; Helgeson BE; Laxman B; Morris DS; Cao Q; Cao X; Andrén O; Fall K; Johnson L; Wei JT; Shah RB; Al-Ahmadie H; Eastham JA; Eggener SE; Fine SW; Hotakainen K; Stenman UH; Tsodikov A; Gerald WL; Lilja H; Reuter VE; Kantoff PW; Scardino PT; Rubin MA; Bjartell AS; Chinnaiyan AM
    Cancer Cell; 2008 Jun; 13(6):519-28. PubMed ID: 18538735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
    Yamoah K; Johnson MH; Choeurng V; Faisal FA; Yousefi K; Haddad Z; Ross AE; Alshalafa M; Den R; Lal P; Feldman M; Dicker AP; Klein EA; Davicioni E; Rebbeck TR; Schaeffer EM
    J Clin Oncol; 2015 Sep; 33(25):2789-96. PubMed ID: 26195723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.
    Huang KC; Dolph M; Donnelly B; Bismar TA
    Clin Transl Oncol; 2014 Nov; 16(11):973-9. PubMed ID: 24796295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.